Oncoinvent ASA (LON:0RU5)
London · Delayed Price · Currency is GBP · Price in NOK | Market Cap | 29.03M |
| Revenue (ttm) | 2.07M +246.4% |
| Net Income | -11.43M |
| EPS | -9.22 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 137 |
| Open | 84.40 |
| Previous Close | 79.40 |
| Day's Range | 84.40 - 84.40 |
| 52-Week Range | 40.20 - 132.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2026 |
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway. [Read more]
Financial Performance
In 2025, Oncoinvent ASA's revenue was 28.07 million, an increase of 246.40% compared to the previous year's 8.10 million. Losses were -155.07 million, 10.6% more than in 2024.
Financial numbers in NOK Financial StatementsNews
Oncoinvent ASA Slides: Investor presentation
Oncoinvent ASA has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.
Oncoinvent ASA Transcript: Investor update
Phase II trial recruitment for Radspherin is progressing well, with 37 patients enrolled and cash reserves supporting operations into 2027. A new Chinese patent was secured, and strategic partnerships are being pursued to extend runway and advance to pivotal studies.
Oncoinvent ASA Slides: Investor update
Oncoinvent ASA has posted slides in relation to its latest quarterly earnings report, which was published on April 29, 2026.
Oncoinvent ASA Slides: DNB Carnegie Nordic Healthcare Conference presentation
Oncoinvent ASA has posted slides in relation to its latest quarterly earnings report, which was published on March 10, 2026.
Oncoinvent ASA Earnings Call Transcript: Q4 2025
Positive phase I ovarian cancer data and strong phase II recruitment marked the period, supported by a NOK 130 million equity raise and a merger, resulting in a NOK 180 million year-end cash balance and a runway into 2027. Clinical expansion and strategic partnerships remain key priorities.
Oncoinvent ASA Quarterly report: Q4 2025
Oncoinvent ASA has published its Q4 2025 quarterly earnings report on February 26, 2026.
Oncoinvent ASA Slides: Q4 2025
Oncoinvent ASA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
Oncoinvent ASA Annual report: Q4 2025
Oncoinvent ASA has published its Q4 2025 annual report on February 26, 2026.
Oncoinvent ASA: Second half 2025 results
OSLO, Norway, Feb. 26, 2026 /PRNewswire/ -- Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity aft...
Oncoinvent ASA Slides: Investor presentation
Oncoinvent ASA has posted slides in relation to its latest quarterly earnings report, which was published on February 3, 2026.
Oncoinvent ASA Transcript: EGM 2026
Shareholders approved a 100-to-1 reverse share split, reduction of nominal share value, and board authorizations for future capital increases. The meeting addressed rationale for these changes, future listing options, and ongoing recruitment updates, with all proposals passing.
Oncoinvent ASA Transcript: EGM 2025
Shareholders approved all agenda items, including a share capital reduction and subsequent increase to facilitate a NOK 130 million rights issue at a new share price of NOK 0.5, with nearly unanimous support for all resolutions.
Oncoinvent ASA Slides: DNB Carnegie Nordic Healthcare Conference presentation
Oncoinvent ASA has posted slides in relation to its latest quarterly earnings report, which was published on November 25, 2025.
Oncoinvent ASA Slides: 7th Targeted Radiopharmaceuticals Summit Europe presentation
Oncoinvent ASA has posted slides in relation to its latest quarterly earnings report, which was published on November 12, 2025.
Oncoinvent ASA Earnings Call Transcript: Q3 2025
Phase I trials in ovarian and colorectal cancer showed strong safety and efficacy signals for Radspherin, with a merger and rights issue extending cash runway into 2027. Phase II ovarian cancer trial recruitment is accelerating, with interim data expected in 2026.
Oncoinvent ASA Slides: Q3 2025
Oncoinvent ASA has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 4, 2025.
Oncoinvent ASA Quarterly report: Q2 2025
Oncoinvent ASA has published its Q2 2025 quarterly earnings report on August 19, 2025.
Oncoinvent ASA Slides: Q2 2025
Oncoinvent ASA has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 19, 2025.